Trial Profile
A Phase 1, Randomized, Double-blind, Placebo Controlled, Monotherapy Study to Assess the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 12 Aug 2020 Results published in the Clinical Therapeutics
- 28 Jun 2011 Results presented at the 71st Annual Scientific Sessions of the American Diabetes Association.
- 03 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.